Inosine
Inosine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target P2Y purinoceptor 4.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rejuvesol | New Drug Application | 2018-02-23 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BB: Antivirals, topical
— D06BB05: Inosine
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AX: Other gynecological antiinfectives and antiseptics in atc
— G01AX02: Inosine
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX05: Inosine pranobex
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA10: Inosine
HCPCS
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
| Closed head injuries | D016489 | — | — | 1 | — | — | 1 | ||
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | — | — | 1 | |
| Obstructive jaundice | D041781 | EFO_1001068 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 1 | — | — | — | 2 |
| Multiple system atrophy | D019578 | — | 1 | — | — | — | 1 | ||
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | 1 | — | — | — | 1 | |
| Postoperative complications | D011183 | — | 1 | — | — | — | 1 | ||
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | 6 | 7 |
| Healthy volunteers/patients | — | 1 | — | — | — | 1 | 2 | ||
| Melanoma | D008545 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphatic diseases | D008206 | HP_0100763 | — | — | — | — | 3 | 3 | |
| Macular edema | D008269 | — | — | — | — | 1 | 1 | ||
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Siderosis | D012806 | J63.4 | — | — | — | — | 1 | 1 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | INOSINE |
| INN | inosine |
| Description | Inosine is a nucleotide that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond. It was discovered in 1965 in analysis of RNA transferase.
Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]cnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O |
Identifiers
| PDB | — |
| CAS-ID | 58-63-9 |
| RxCUI | 1483575 |
| ChEMBL ID | CHEMBL1556 |
| ChEBI ID | 17596 |
| PubChem CID | 6021 |
| DrugBank | DB04335 |
| UNII ID | 5A614L51CT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000014747 | ITPA, 124+21A>C | drug response | 2021-03-24 | 2B |
| VCV000014746 | ITPA, 94C>A, Pro32Thr | drug response | 2021-03-24 | 2B |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 25,269 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
51 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more